Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161234 | 0.87 | CES2 (0.40) | HSD11B1PTGS1 | |
| SCHEMBL4614322 | 0.85 | CES2 (0.42) | PTGS1 | |
| SCHEMBL4014971 | 0.84 | NFE2L2 (0.65) | NFE2L2PTGS1HTR2AHTR2CKCNH2 | |
| Ammonia Solution, Strong SCHEMBL4615643 | 0.83 | CES2 (0.40) | HSD11B1PTGS1 | |
| SCHEMBL11323370 | 0.83 | CES2 (0.40) | HSD11B1PTGS1 | |
| SCHEMBL3162012 | 0.76 | NFE2L2 (0.48) | HSD11B1NFE2L2PTGS1HTR2AHTR2C | |
| SCHEMBL3162027 | 0.76 | NFE2L2 (0.48) | HSD11B1NFE2L2PTGS1HTR2AHTR2C | |
| SCHEMBL700051 | 0.75 | NFE2L2 (0.78) | HSD11B1NFE2L2PTGS1TNFRSF1APTGS2 | |
| SCHEMBL11859127 | 0.75 | CA1 (0.33) | — | |
| SCHEMBL22468800 | 0.75 | NFE2L2 (0.78) | HSD11B1NFE2L2PTGS1TNFRSF1APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807393-B1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | CASTRO PINEIRO JOSE LUIS | 2009-07-02 | — | — | US | disclosed |
| EP-1858852-B1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-7468393-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-12-23 | — | — | US | disclosed |
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | GILLIGAN MYRA | 2008-11-13 | — | — | US | disclosed |
| EP-1858852-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-11-28 | — | — | EP | disclosed |
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1807393-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | Merck Sharp & Dohme Limited (GB) | 2007-07-18 | — | — | EP | disclosed |
| US-7217740-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP AND DOHME | 2007-05-15 | — | — | US | disclosed |
| WO-2006095205-A1 | HETEROARYLSULFONYL STILBENES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203205-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | HSD11B1 951/4885NFE2L2 3662/4885PTGS1 794/4885 |
| US-20080280956-A1 | Heteroarylsulfonyl Stilbenes as 5-Ht2a Antagonists | HTR2A, HTR2B, HTR2C | HSD11B1 894/4885NFE2L2 2791/4885PTGS1 426/4885 |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | HSD11B1 951/4885NFE2L2 3662/4885PTGS1 794/4885 |
| US-20090170824-A1 | Diarylsulfones as 5-HT2A Antagonists | HTR2A, HTR2B, HTR1A | HSD11B1 951/4885NFE2L2 3662/4885PTGS1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.